Phase I Trial of Intraperitoneal 212-Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy.
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs 212 Pb TCMC trastuzumab (Primary)
- Indications Breast cancer; Colon cancer; Endometrial cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AREVA Med; Orano Med
- 23 Jan 2018 According to an Orano Med media release, AREVA Med changed its name to Orano Med.
- 29 Sep 2016 Status changed from active, no longer recruiting to completed.
- 18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov records.